New version of ovarian cancer drug tested for safety and effectiveness
NCT ID NCT07371104
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new version of the drug olaparib (DWZ2501) works as well as the current version (DWC202510) in women with advanced BRCA-mutated ovarian cancer. About 40 participants will take both versions at different times to compare drug levels and safety. The goal is to confirm the new version is a suitable replacement for ongoing treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BRCA-MUTATED HIGH-GRADE OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institutional Review Board of Seoul National University Hospital
RECRUITINGSeoul, Jongno-gu, 03080, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- A virtual Walk-Through of radiotherapy may calm cancer Patients' nerves
- Money worries and cancer: can talking about both ease the burden?
- Can a custom mRNA vaccine keep ovarian cancer from coming back?